SOURCE: InoLife Technologies Inc.

December 02, 2010 10:43 ET

InoLife Technologies, Inc. Welcomes David Klein as Vice President of Business Development

Mr. Klein Brings 20 Plus Years of Experience in Developing New Business and Building Corporate Identities

RALEIGH, NC--(Marketwire - December 2, 2010) - InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today that it has hired Mr. David Klein as Vice President Of Business Development. The company looks forward to working with David to bring Brand Recognition to our current and future DNA-based testing products to the medical industry.

David Klein began his 20-year career at Burson-Marsteller, a leading global public relations and communications firm. While at Burson-Marsteller, David was successful in the development of accounts and generating new business by building brand recognition. His responsibilities also included building studies relative to the market place to convince clients that their best interests lie with B-M as their PR firm.

Prior to joining InoLife, David consulted in developing new business for NYU Hospital, KPMG Peat Marwick, Deloitte & Touche, American Express, Citigroup, and JPMorgan Chase. David also worked as a Program Manager for Ernst & Young, managing a team of more than 200 professionals that installed a General Ledger and Banking Applications for MetLife Insurance Co.

David graduated with a Bachelor's Degree from the University of Delaware in 1991 and holds Series 7, 55, and 63 licenses.

"All of my consulting experience is beneficial to InoLife, especially Ernst & Young, in that I learned a methodology which translates directly to ROI. This is my goal for InoLife, to increase shareholder value," stated Mr. Klein.

David believes in InoLife's mission, which is to increase awareness of an individual's health and to provide that individual and his doctor with genetic information so relevant, that as patient and doctor, they can act upon the best healthcare decisions available.

By doing this, we expect to capture a significant share of the genetic testing market by building a national network of medical and healthcare professionals that will employ our products due to their superior information collection techniques, reporting tools, ease of use, and trust in our brand.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information